Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00100581 · ClinicalTrials.gov registry record · NA

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

A NA study of HIV Infections and Hepatitis C, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
2
Enrollment target
2
Study locations

NCT00100581 is a NA study of HIV Infections and Hepatitis C that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00100581, a NA study of HIV Infections and Hepatitis C, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
2 participants
Enrollment target
2
Study locations

Study Summary

A significant proportion of HIV infected people in the U.S. are also infected with hepatitis C virus (HCV). The purpose of this study is to determine the effects of anti-HIV therapy on treatment of HCV with pegylated interferon alfa-2a and ribavirin (PEG/RBV).

Conditions Studied

HIV Infections Hepatitis C

Interventions

  • DRUG Lamivudine
  • DRUG Efavirenz
  • DRUG Ribavirin
  • DRUG Lopinavir/ritonavir
  • DRUG Pegylated interferon alfa-2a

Study Locations (2)

New York

  • Columbia Univ., HIV Prevention and Treatment Medical Ctr. - New York

Texas

  • Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic - Dallas

Trial Details

FieldValue
Enrollment Target 2 participants
Est. Completion 2007-01
Phase NA

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00100581

The ClinicalTrials.gov registry entry for NCT00100581 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Lamivudine is the first listed.

NCT00100581 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.

Frequently Asked Questions

What is clinical trial NCT00100581 about?

NCT00100581 is a clinical study titled "Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults". A significant proportion of HIV infected people in the U.S. are also infected with hepatitis C virus (HCV). The purpose of this study is to determine the effects of anti-HIV therapy on treatment of HCV with pegylated interferon alfa-2a and ribavirin (PEG/RBV).

What is the current status of trial NCT00100581?

This trial is currently completed. It is a NA study. The enrollment target is 2 participants. Estimated completion is 2007-01.

What conditions does trial NCT00100581 study?

This clinical trial studies the following conditions: HIV Infections, Hepatitis C.

What interventions are being tested in trial NCT00100581?

The interventions under investigation include: Lamivudine (DRUG), Efavirenz (DRUG), Ribavirin (DRUG), Lopinavir/ritonavir (DRUG), Pegylated interferon alfa-2a (DRUG).

Who is sponsoring clinical trial NCT00100581?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00100581 being conducted?

This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Hepatitis C

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.